StemoniX® to Present at 31st Annual ROTH Conference

StemoniX® to Present at 31st Annual ROTH Conference

Back to Latest News StemoniX®to Present at 31stAnnual ROTH Conference MAPLE GROVE, MN, MARCH 13, 2019 – StemoniX®Inc., a biotech company revolutionizing how new medicines are discovered, announced today that its co-founder and CEO, Ping Yeh, will present at the 31stAnnual ROTH Conference being held March 17-19, 2019, at The Ritz Carlton in Dana Point, CA. [...]
Axios Newsletter

Axios Newsletter

Axios: StemoniX Lands $14.4M to Continue Development of ‘Micro-Organs’ March 1, 2019 – StemoniX Inc, a Minnesota-based biotech company, has secured $14.4 million in Series B funding led by Brightstone Venture Capital, with Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic also participating. Read more here
FierceBiotech

FierceBiotech

StemoniX rakes in $14.4M for micro-organ drug testing chips built from stem cells’ February 28, 2019 – Microtissue developer StemoniX has secured $14.4 million in funding to commercialize its organ-on-a-chip platforms for drug development. Read more here
MinneInno Article

MinneInno Article

MinneInno: StemoniX Lands $14.4M to Continue Development of ‘Micro-Organs’ February 28, 2019  – StemoniX, a biotech startup using stem cells to create micro-organs for drug testing and development, has raised $14.4 million in a fresh round of funding, the company announced Thursday. Read more here
The PE Hub Network

The PE Hub Network

The PE Hub Network: Biotech company StemoniX nets $14.4 mln Series B February 28, 2019 – Minnesota-based StemoniX Inc, a biotech company, has secured $14.4 million in Series B funding. Brightstone Venture Capital led the round with participation from other investors that included Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic. Read more here
WSJ Venture Capital

WSJ Venture Capital

WSJ Venture Capital: Term Sheet Friday March 1, 2019 – StemoniX Inc, a Minnesota-based biotech company, raised $14.4 million in Series B funding. Brightstone Venture Capital led the round, and was joined by investors including Crescent Ridge Partners, SEED San Diego, Alumni Ventures Group, Keshif Ventures and Mayo Clinic. Read more here
StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

Back to Latest News StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms Series B financing will drive expansion of commercial operations and development of new microOrgan® platforms MAPLE GROVE, MN, FEBRUARY 28, 2019 – StemoniX® Inc., a biotech company revolutionizing how new medicines are discovered, announced today that it has secured [...]
StemoniX Uses microBrain 3D, a Functional In Vitro Human Neural Model, to Identify Potential Treatment Modalities for Rett Syndrome

StemoniX Uses microBrain 3D, a Functional In Vitro Human Neural Model, to Identify Potential Treatment Modalities for Rett Syndrome

Back to Latest News StemoniX® Uses microBrain® 3D, a Functional In Vitro Human Neural Model, to Identify Potential Treatment Modalities for Rett Syndrome Research Presented During Podium Session at SLAS2019 Highlights the Application of microBrain 3D to Identify Potential Therapeutic Compounds for Neurodevelopmental Disorders   MAPLE GROVE, MN, FEBRUARY 14, 2019 – StemoniX® Inc., a biotech [...]
February 2019 Pipette.com article on Ping Yeh

February 2019 Pipette.com article on Ping Yeh

Back to Latest News STEMONIX PRODUCTS ALLOW DOCTORS TO SEE HOW DRUGS AND HUMAN CELLS REACT WITHOUT RISKING A PERSON’S HEALTH. Month 1, 2018 – Ping Yeh fought a tough battle with blood cancer and survived, but the effects linger five years later. Yeh is cancer-free, but he still deals with side effects like neuropathy from [...]